Recent advances in pediatrics.
The challenging issues in pediatric pharmacotherapy are both profound and exciting. Microtechnologies for evaluating the impact of genetics in disease (e.g., using polymerase chain reactions) and the possibilities of therapeutic interventions create major clinical and ethical dilemmas that remain to be resolved. Inclusion of pediatric patients in drug development and marketing trials also remains a point of contention. Finally, well-established therapies should not be overlooked in favor of new but unestablished treatment approaches. Future columns will continue to use the current format, in which a few selected topics of high therapeutic importance are discussed. The research technologies, discussion of new drug therapy interventions, and preventive strategies most likely to benefit the health care of infants, children, and adolescents will remain the scope of this column.
Gal
P
P
Greensboro AHEC, Moses H. Cone Memorial Hospital, NC 27401.
Reed
M D
MD
Nahata
M C
MC
D000293:Adolescent; D000932:Antiemetics / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000009:adverse effects / Q000378:metabolism; D005466:Fluorocarbons / Q000627:therapeutic use; D006801:Humans; D006937:Hypercholesterolemia / Q000175:diagnosis; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000209:etiology; D007223:Infant; D007231:Infant, Newborn; D009569:Nitric Oxide / Q000627:therapeutic use; D010372:Pediatrics / Q000639:trends*; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy; D014611:Vaccination; D014810:Vitamin E / Q000378:metabolism / Q000627:therapeutic use
D000932:Antiemetics; D005466:Fluorocarbons; D014810:Vitamin E; D009569:Nitric Oxide; D016572:Cyclosporine